JAPAN-SANITARY-EQUIP-IND
26.7.2022 04:02:07 CEST | Business Wire | Press release
The Japan Sanitary Equipment Industry Association, which is composed of Japanese companies engaged in the manufacturing of toilets (Headquarters: Nagoya, Aichi, Japan. President: Noriaki Kiyota [President & Representative Director of TOTO Ltd.], hereinafter “Association”) is proud to announce that the number of warm water spray seat shipments since the industry began tracking statistics (1987) has reached 100 million units as of June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005331/en/
The Road to 100 Million Units
The start of importation and sale of toilets and toilet seats with warm-water washing functionality into Japan in 1964 sparked major changes of “washing bottoms” in Japanese toilets. At first, sales were targeted towards medical facilities, and use was not widespread. Later, domestic production began, and companies launched initiatives including product development and improvement, and sales promotions to encourage use in common households. Eventually, more Japan residents grew to recognize these products after a TV commercial in 1982. Once people experienced the comfort of a warm toilet seat and the refreshing satisfaction of rear cleansing, they were unable to live without it. Good reputations spread, and these products finally became accepted by the general public.
Association member companies have been working continuously to evolve these products and to promote further use, by making new proposals and implementing updates that reflect consumer needs across multiple aspects, including function, comfort, hygiene, design, and energy efficiency. Currently in 2022, usage rates in general households have surpassed 80%, which means that it can finally be said that these products are estimated to be used in the majority of general households with flushable toilets. Likewise, because warm water spray seats have a good reputation for comfort, they have also been widely adopted for use in public places such as office buildings, commercial facilities, hotels, trains, and train stations.
Must-Have Item for Japanese Bathrooms
According to an awareness survey conducted by the Association in 2022 among warm water spray seat users in Japan, the main reason for use was “It’s sanitary and feels good to use.” In addition, 97% of the respondents would like to continue to use the warm-water washing toilet seats, indicating that once they use them, they find it so comfortable that they will not want to give them up.
Meanwhile, outside of Japan, demands are growing in other countries across the Americas, Europe, Asia, and the Middle East in recent years as interest in hygiene continues to rise, and the international market for warm water spray seats continues to expand every year. In particular, a sudden rise in demand was seen in North America in 2020, stoking anticipation for wider usage in the near future.
The Association and its members, Japanese manufacturers of warm water spray seats, are dedicated to making real improvements in restroom culture worldwide through the wider usage of sanitary and comfortable warm water spray seats in every country.
Awareness Survey for Warm Water Spray Seat Users
Survey Method: Online questionnaire
Survey Targets: Users of warm-water washing toilet seats, aged 10 to 79, living in Japan, 150 respondents for each age group, total of 2,100 respondents
Survey Period: February 4, 2022 (Friday) to February 7, 2022 (Sunday)
[ Survey Results Summary ]
The main reason for use was “It’s sanitary and feels good to use.”
When asked why they use warm water spray seats, most respondents said “It removes waste well and keeps me clean” (82%) and nearly half of respondents said “It feels good and refreshing” (48%).
97% of respondents said “I want to continue using it.”
Regarding their intention to continue the use of warm-water toilet seats in the future, 86% of respondents said they would like to continue to use them, and 11% said they would rather continue to use them.
Learn More About the Japan Sanitary Equipment Industry Association
The Japan Sanitary Equipment Industry Association is an industry organization made up of toilet equipment manufacturers that handle products such as sanitary fixtures (large and small toilets) and warm-water washing toilet seats.
The Japan Sanitary Equipment Industry Association operates the JAPAN TOILET INFORMATION website, which is dedicated to providing information on toilet conditions in Japan (usage, signage, etc.) for foreign visitors to Japan.
(https://www.sanitary-net.com/utsukushitoilet/en/
)
[ Member Companies (As of June 2022, in alphabetical order) ]
Aisin Corporation, Asahi Eito Co., Ltd., Janis Ltd., Lixil Corporation, Panasonic Holdings Corporation, SAN-EI Faucet Mfg Co., Ltd, Toshiba Lifestyle Products & Services Corporation, TOTO Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
